Beyond Keytruda: Merck’s Oncology Pipeline Expansion Through M&A
Is Merck ready to face the looming patent cliff? Impact of Inflation Reduction Act (IRA) on Keytruda Inflation Reduction Act (IRA) was passed in 2022
Is Merck ready to face the looming patent cliff? Impact of Inflation Reduction Act (IRA) on Keytruda Inflation Reduction Act (IRA) was passed in 2022
The US FDA approval of Fresenius Kabi’s Tyenne®, the first Tocilizumab biosimilar with both intravenous and subcutaneous formulations, is a breakthrough in bringing high-quality, affordable,
Patent linkage system serves as a crucial tool in the pharmaceutical industry, strategically aligning the approval process of generic drugs with the patent status of
Rivaroxaban, marketed under the brand name Xarelto®, has emerged as a pivotal therapeutic option for various cardiovascular conditions, revolutionizing the landscape of anticoagulant therapy. Its
With the recent approval of the first two interchangeable biosimilars to Amgen’s PROLIA® and XGEVA® by the US FDA in March 2024, the overall count
The final versions of the updated Guidelines for Patent Examination and the Implementing Rules for the Patent Law were released by the China National Intellectual
Welcome to World School of Life Sciences IP, a pioneer in empowering minds to dominate the ever-evolving landscape of patents and pharmaceutical innovations.
Copyright 2023 All right reserved by WSLI. Designed by Webpeckers.